BIO report shows lagging innovation for pain, addiction

The Biotechnology Innovation Organization called attention to lower venture funding and fewer clinical-stage novel compounds within pain and addiction indications in its second report in a series on funding and R&D for highly prevalent chronic diseases.

"Lower investment and pipeline breadth in pain and addiction relative to other disease areas with high societal health burdens demonstrates the need for incentivizing more research and clinical development," BIO said...